Duchenne muscular dystrophy

D Duan, N Goemans, S Takeda, E Mercuri… - Nature reviews disease …, 2021 - nature.com
Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disease that leads
to difficulties with movement and, eventually, to the need for assisted ventilation and …

Duchenne muscular dystrophy: disease mechanism and therapeutic strategies

A Bez Batti Angulski, N Hosny, H Cohen… - Frontiers in …, 2023 - frontiersin.org
Duchenne muscular dystrophy (DMD) is a severe, progressive, and ultimately fatal disease
of skeletal muscle wasting, respiratory insufficiency, and cardiomyopathy. The identification …

Life expectancy in Duchenne muscular dystrophy: reproduced individual patient data meta-analysis

J Broomfield, M Hill, M Guglieri, M Crowther, K Abrams - Neurology, 2021 - neurology.org
Background and Objectives Duchenne muscular dystrophy (DMD) is a rare progressive
disease that is often diagnosed in early childhood and leads to considerably reduced life …

Natural history and real‐world data in rare diseases: applications, limitations, and future perspectives

J Liu, JS Barrett, ET Leonardi, L Lee… - The Journal of …, 2022 - Wiley Online Library
Rare diseases represent a highly heterogeneous group of disorders with high phenotypic
and genotypic diversity within individual conditions. Due to the small numbers of people …

Emerging therapies for Duchenne muscular dystrophy

T Markati, M Oskoui, MA Farrar, T Duong… - The Lancet …, 2022 - thelancet.com
Duchenne muscular dystrophy is an X-linked disease caused by the absence of functional
dystrophin in the muscle cells. Major advances have led to the development of gene …

Therapeutic developments for Duchenne muscular dystrophy

IEC Verhaart, A Aartsma-Rus - Nature Reviews Neurology, 2019 - nature.com
Duchenne muscular dystrophy (DMD) is caused by the lack of functional dystrophin protein.
Improvements in patient care and disease management have slowed down disease …

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial

JR Mendell, F Muntoni, CM McDonald, EM Mercuri… - Nature medicine, 2025 - nature.com
Duchenne muscular dystrophy (DMD) is a rare, X-linked neuromuscular disease caused by
pathogenic variants in the DMD gene that result in the absence of functional dystrophin …

Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

E Mercuri, JJ Vilchez, O Boespflug-Tanguy… - The Lancet …, 2024 - thelancet.com
Background Duchenne muscular dystrophy, the most common childhood muscular
dystrophy, is caused by dystrophin deficiency. Preclinical and phase 2 study data have …

Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial

M Guglieri, PR Clemens, SJ Perlman, EC Smith… - JAMA …, 2022 - jamanetwork.com
Importance Corticosteroidal anti-inflammatory drugs are widely prescribed but long-term use
shows adverse effects that detract from patient quality of life. Objective To determine if …

Drug development progress in duchenne muscular dystrophy

J Deng, J Zhang, K Shi, Z Liu - Frontiers in Pharmacology, 2022 - frontiersin.org
Duchenne muscular dystrophy (DMD) is a severe, progressive, and incurable X-linked
disorder caused by mutations in the dystrophin gene. Patients with DMD have an absence of …